Recent studies indicate that eculizumab is often given in excess to atypical hemolytic uremic syndrome (aHUS) patients. Individualization of treatment is thus highly requested; however, data on the pharmacokinetics and pharmacodynamics of eculizumab remain limited. We analyzed 11 patients during induction ...
Eculizumab (brand names Soliris, Bkemv, and Epysqli) is used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (HUS), generalized Myasthenia Gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
We evaluated its efficacy and safety in pediatric patients with TMA sub-types: atypical HUS (aHUS), Shiga toxin-producing Escherichia coli (STEC)-HUS, and transplant-associated TMA (TA-TMA). Methods: This retrospective study included all pediatric patients treated with e...
1 1.1 INDICATIONS AND USAGE Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. 1.2 Atypical Hemolytic Uremic Syndrome (aHUS) Soliris is indicated for the treatment of patients with atypical ...
SOLIRIS is used to treat adults and children with a disease called atypical Hemolytic Uremic Syndrome (aHUS). SOLIRIS is not for use in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). SOLIRIS is used to treat adults with a disease called generalized ...
16. What are the treatments available for atypical HUS? Anticomplement therapy is now the standard of care for the treatment of aHUS. Eculizumab is a humanized monoclonal antibody directed against C5 of the complement cascade and thereby inhibits the formation of C5a and C5b-9 membrane attack ...
atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy Limitation of Use: Epysqli is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). ...
AMSTERDAM —Eculizumableads to clinically meaningful improvements in thrombotic microangiopathy and reverses renal damage in adults with atypicalhemolytic uremic syndrome(aHUS), regardless of transplant history, new research shows. After the introduction of eculizumab, most patients were able to discontinue ...
The most common etiologies of HUS are the ones seen in childho... JC Verhave,Wetzels Jack F.M.,van de Kar Nicole C.A.J. - 《Nephrology Dialysis Transplantation》 被引量: 186发表: 2014年 Pre-emptive Eculizumab and Plasmapheresis for Renal Transplant in Atypical Hemolytic Uremic Syndrome ...
Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation Am J Transplant (2012) D Murray et al. Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions Pharmacol Ther (2013) J Suh et al. Clinical characteristics of refractory ...